Compare Smith & Nephew plc (SNN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs BIO-TECHNE Corp — how do they compare? Smith & Nephew plc trades at $27.08 (market cap $11.31B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Smith & Nephew plc and BIO-TECHNE Corp are close in size by market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and BIO-TECHNE Corp for 63 Days on average.
| SNN | TECH | |
|---|---|---|
Market Cap | $11.31B | $11.37B |
Volume | 1,050,005 | 3,153,511 |
Sector | Health | Health |
52-Week High | $37.17 | $72.61 |
52-Week Low | $26.42 | $43.31 |
Typical Hold Time | 120 Days | 63 Days |
Enterprise Value | $14.35B | $11.40B |
Dividend Yield | 2.95% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
